Nektar Therapeutics (NKTR) Tops Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $74.68 +1.41%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
ZTO, AMMX, AFIB, More
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
ZTO, AMMX, AFIB, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.18), $0.02 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $24.12 million versus the consensus estimate of $21.65 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Essity to buy Kenvue's feminine care brands in Brazil for $284m
- Stripe agrees to acquire AI model routing platform OpenRouter
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
